Markets:

Overview

News

Currencies

International

Treasuries

Ipsen S.A. (OP:IPSEF)

113.13 UNCHANGED

Last Price Updated: 3:47 PM EDT, Jun 9, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ipsen S.A.

Third Time Lucky: Exelixis' Cabozantinib Combo Therapy Aces Pivotal Study In Prostate Cancer Patients ↗

August 21, 2023

Roche Holdings AG (OTC: RHHBY), Exelixis Inc (NASDAQ: EXEL), and Ipsen&nbs

Via Benzinga

What Now After FDA AdComm Rebuke for Intercept Pharmaceutical? Analyst Says Approval Of Intercept's 'OCA In NASH May Never Occur ↗

May 22, 2023

On Friday, FDA's Gastrointestinal Drugs Advisory Committee voted 12 to 2—with two abstentions—that the benefits of Intercept Pharmaceutical Inc's ICPT Ocaliva 25 mg, also known as Obeticholic acid...

Via Benzinga

France-Based Ipsen Acquires Albireo Pharma Enriching Its Rare Disease Portfolio, Pipeline ↗

January 09, 2023

Via Benzinga

Why Merrimack Shares Are Surging Over 200% Today? ↗

November 09, 2022

Via Benzinga

Merrimack Pharma-Ipsen's Cancer Drug Fails In Overall Survival Measure ↗

August 03, 2022

Via Benzinga

Why Is Epizyme (EPZM) Stock Up 75% Today? ↗

June 27, 2022

EPZM stock is jumping higher today on news that Epizyme is being acquired by French pharmaceutical company Ipsen.

Via InvestorPlace

Ipsen Scoops Up Blood Cancer-Focused Epizyme - Read Why ↗

June 27, 2022

Ipsen SA (OTC: IPSEY) has

Via Benzinga

Ipsen - Exelixis' Cabometyx Scores European Approval As Second-Line Treatment For Thyroid Cancer ↗

May 03, 2022

Via Benzinga

EMA's Scientific Committee Backs Expanded Use Of Exelixis, Ipsen's Cabometyx In Thyroid Cancer ↗

March 25, 2022

Exelixis Inc (NASDAQ: EXEL) and its partner Ipsen SA (OTC: IPSEY) have

Via Benzinga

Ipsen's Sohonos Scores Canadian Approval For Rare Connective Tissue Disease ↗

January 24, 2022

Health Canada has approved Ipsen SA's (OTC: IPSEY) Sohonos (palovarotene capsules) in adults and children aged eight years & above for fibrodysplasia ossificans...

Via Benzinga

Genfit Shares Rally After Ipsen Buys Rights To Its Late-Stage Kidney Disease Treatment Hopeful ↗

December 17, 2021

Ipsen SA (OTC: IPSEY) has entered into a long-term strategic partnership to develop, manufacture, and commercialize and Genfit SA's (NASDAQ: GNFT)...

Via Benzinga

Ipsen Stock Declines After Pulling Rare Disease Application ↗

August 13, 2021

Ipsen (OTC: IPSEY) withdrew its US marketing application for palovarotene following discussions with the FDA indicating additional data analyses needed from two...

Via Benzinga

Exicure Stock Surges On Over $1B Option Licensing Pact With Ipsen For Rare Neurodegenerative Disorders ↗

August 02, 2021

Ipsen SA (OTC: IPSEY) and Exicure Inc (NASDAQ: XCUR) have collaborated to research, develop, and commercialize novel Spherical Nucleic Acids (SNAs) as...

Via Benzinga

Ipsen Beefs Up Pre-Clinical Oncology Pipeline With Over $850M Deal With BAKX Therapeutics ↗

July 27, 2021

Ipsen SA (OTC: IPSEY) and privately-held BAKX Therapeutics Inc have signed an exclusive worldwide collaboration agreement to research, develop,...

Via Benzinga

Exelixis Shares Drop On Mixed Results For Cabometyx Combo In Early Liver Cancer ↗

June 28, 2021

Exelixis Inc (NASDAQ: EXEL) and Ipsen (OTC: IPSEY) have announced mixed interim results from the COSMIC-312 Phase 3 trial evaluating cabozantinib (...

Via Benzinga

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Ipsen S.A. (OP:IPSEF)

All News about Ipsen S.A.

Starting at $3.75/week.

Subscribe Today